Drug intelligence / Profile preview

SBG003

Development stage
Preclinical
Lead developer
Sonoran Biosciences
Modality
Hydrogel Systems → Drug Delivery Systems, Small Molecules
Administration
Surgical Implant, Topical, Intracavitary
01

Overview

**SBG003** is Sonoran Biosciences' preclinical, fixed-dose local antimicrobial product for prevention of surgical site infection. It combines the aminoglycoside antibiotic **tobramycin** and the glycopeptide antibiotic **vancomycin** in the proprietary SB Gel extended-release, injectable hydrogel system. Following intraoperative instillation, the formulation conforms to surgical-site surfaces, forms a local gel depot, and releases antibiotics over multiple days to provide sustained local concentrations while limiting systemic exposure. SBG003 is intended for high-risk procedures including abdominal, colorectal, cardiac, and orthopaedic surgery; it has shown activity in preclinical colorectal and orthopaedic surgical-site-infection models and received FDA Qualified Infectious Disease Product designation for prevention of surgical site infection after abdominal surgery. ([sonoranbiosciences.com](https://www.sonoranbiosciences.com/sbg003/))

Other names
tobramycin + vancomycin extended-release solutiontobramycin + vancomycin hydrogel
02

Targets

Bacterial RibosomeLipid II

Beyond the preview

Go deeper on SBG003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBG003.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call